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The purpose of this study was to clarify the effect of orthotopic 
liver transplantation on hypersplenism. In a I-year period from 
July 1, 1986 to June 30,1987,196 adult patients underwent 233 
orthotopic liver transplantations. Of the 58 patients with hy-
persplenism who were analyzed in this study, hypersplenism was 
more commonly associated with postuecrotic cirrhosis than other 
kinds of liver disease (55.3% (47/85) "S. 14.5% (11/76); p 
< 0.0(1». Postoperative platelet counts were statistically higher 
than preoperative values (p < 0.05). The latest platelet counts 
were more than lOO,OOO/mm3 in 53 patients (91.4%). Of the 
eight patients whose preoperative and postoperative spleen vol-
umes could be compared, all showed the reduction in the spleen 
size (p < 0.02). We conclude that orthotopic liver transplantation, 
wbich is a radical surgical procedure for portal hypertension, 
reverses hypersplenism. 
Pennsylvania I 
H YPERSPLENISM IS FREQUENTLY ASSOCIATED with liver cirrhosis, which· commonly pre~ents 
itself as splenomegaly with hematologic disor-
ders, i.e., leukopenia, thrombocytopenia, and anemia. 1 
The incidence of hypersplenism among cirrhotics varies 
from 15% to 70%,1 and splenectomy is known to relieve 
the hematologic disorders associated with this clinical en-
tity.2-4 Passive congestion of the spleen due to portal hy-
pertension is thought to cause the splenomegaly, which 
results in the sequestration and the destruction of the 
blood elements.5,6 Although portacaval and distal sple-
norenal shunts are known to reduce the splenic vein pres-
sure, the effect of these shunts on hypersplenism remains 
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controversial. I- 9 Orthotopic liver transplantation (OLTx), f 
which has become an accepted modality of treatment for 
end-stage liver disease,IO,11 is a radical surgical procedure 
for portal hypertension. The purpose of this study was to 
evaluate the effect of OL Tx on hypersplenism. 
Patients and Methods 
In a I-year period between July 1, 1986 and June 30, 
1987, 196 adult patients underwent 232 orthotopic liver 
transplantations (OLTx) at the Presbyterian University 
Hospital of Pittsburgh, University of Pittsburgh. Their 
ages ranged from 19 to 76 years, with a mean of 44.9 
years; 85 patients were men (43.4%). The indications for 
OL Tx consisted of postnecrotic cirrhosis in 10 1 patients, 
(21 alcoholic, 80 nonalcoholic), primary biliary cirrhosis 
in 41, primary sclerosing cholangitis in 20, neoplasm in 
10, and other indications in 24 patients. Sixty-three of 
these patients (32.1 %) demonstrated evidence of hyper-
splenism, as indicated by leukocyte counts of less than 
5000/cmm and/or platelet counts ofless than 100,0001 
cmm, and had follow-up periods of more than 3 months. 
The age among these patients varied from 21 to 76 years, 
with a mean of 45.6, and 34 were men (54%). The indi-
cations for OLTx were postnecrotic cirrhosis in 47 patients 
(10 alcoholic, 37 nonalcoholic), primary biliary cirrhosis 
in 5, primary sclerosing cholangitis in 4, neoplasm with 
postnecrotic cirrhosis in I, and other indications in 6 pa-
tients. Follow-up periods ranged from 133 to 547 dayS, 
with a mean of355 days. Three of these patients developed 
pathologic thrombocytopenia: aplastic anemia, idiopathJC 
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thrombocytopenic purpura, and systemic cytomegalovirus 
infection, respectively. These patients, as well as two other 
patients who underwent in~erferon treatment for the pre-
vention of recurrent hepatItIS B, were excluded from the 
investigation of the change in the platelet counts. The 
remaining 58 patients were analyzed in this study. The 
immunosuppressive regimen consisted ofCyclosporin and 
corticosteroids. Steroid-resistant rejection was treated 
with Orthoclone OKT@3 (Ortho Pharmaceutical Co., 
Raritan, NJ). 
Serial platelet counts were obtained from the charts on 
postoperative days 7, 14, 21, and 30. The most recent 
platelet counts were acquired from the outpatient clinic 
or from the family physicians. Postoperative leukocyte 
counts were not evaluated because of the effect of post-
operative immunosuppression on the peripheral leukocyte 
counts. 
In 8 patients with hypersplenism, the spleen volume 
was measured from computed tomograms (CT) taken be-
fore and 22 to 80 days after operation, with a mean of 41 
days after 0 L Tx; these measurelTU!nts were used for com-
parison of changes in spleen size. 
Paired Student's and Chi-square tests were used in the 
statistical evaluation in this study. 
Results 
Table 1 lists the incidence of hypersplenism in relation 
to indications for OLTx among patients who underwent 
OLTx and had follow-up periods of more than 3 months. 
The incidence of hypersplenism was significantly higher 
in patients with end-stage liver disease due to postnecrotic 
cirrhosis, either alcoholic or nonalcoholic in etiology (p 
< 0.001, X2 = 29.08). 
Table 2 lists the changes in the platelet counts in dif-
ferent categories. The patients with postnecrotic cirrhosis, 
either alcoholic or nonalcoholic, demonstrated statistically 
significant increases beginning with postoperative day 14 
(p < 0.05 or less). In the patients with primary biliary 
cirrhosis, a statistically significant difference was observed 
TABLE I. indicalionsJor Orthotopic Lhw Transp/antalion 
and the Incidence o(Hypersp/enism 
Patients 
Indication Total With Hypersplenism 
Post necrotic cirrhosist 85 47 (55.3%) 
Alcoholic 16 9 (56.3%) 
Nonalcoholic 69 38 (51.1%) 
Primary biliary cirrhosis* 36 5 ( 13.9%) 
Otherst 40 
Primary sclerosing 
6 (15%) 
cholangitis 18 3 (16.7%) 
Tumor 8 2* (25%) 
Fulminant hepatitis 5 0 
Alpha-I-antitrypsin 
deficiency 4 I (25%) 
Hemochromatosis 2 0 
Wilson's disease I 0 
Others 2 0 
Total 161 58 (36%) 
* Both patients had associated liver cirrhosis. 
p < 0.001 (X2 = 29.08) when the incidence of hypersplenism was 
compared between t and * 
between the preoperative and the current platelet counts 
(p < 0.05). In patients with other diseases, statistical dif-
ferences from the preoperative platelet counts were ob-
served on ppstoperative day 14. Overall, as shown in Fig-
ure 1, the increase in platelet counts after OL Tx in patients 
with hypersplenism was statistically significant. The 
platelet counts on postoperative days 7, 14, 21, 30, and 
the current or last platelet counts were significantly higher 
than the preoperative values (p < 0.05, 0.001, 0.001, 
0.001, and 0.001, respectively). The latest platelet 
counts are more than 100,000/mm3 in all but five pa-
tients (91.4%). 
Table 3 lists the changes in the spleen size after OLTx 
with the use of CT in eight patients with hypersplenism. 
All patients showed the reduction in the spleen volume, 
7% to 50%, with a mean of 23.1 %, which was a statistically 
significant volume reduction as compared to the preop-
erative spleen size (p < 0.02). 
TABLE 2. Changes in Platelet Counts Following Orthotopic Liver Transplantation in Patients with Hypersplenism 
Platelet Counts (fmm3) 
Postoperative Day 
Indications Preoperative 7 14 21 30 Current 
PNC-A (n = 9) 69 ± 26 73 ± 46 234 ± 123t 193 ± 79* 152 ± 58t 216 ± 156* 
PNC-NA (n = 38) 63 ± 17 72 ± 38 185 ± 101* 176± 99" 164 ± 8411 168 ± 72" 
PBC (n = 5) 87 ± 7 120 ± 65 240 ± 247 218 ± 137 242 ± 153 224 ± 117* 
l~hers (n = 6) 79 ± 16 119 ± 79 232 ± 145* 197 ± 125 198 ± 164 271 ± 215 
* p < 0.05, tp < 0.01, *p < 0.005 and lip < 0.0001 when compared 
to preoperative values (paired Student's t-test); PNC-A. postnecrotic cir-
rhosis, alcoholic; PNC-NA, postnecrotic cirrhosis, nonalcoholic; PBC, 
primary biliary cirrhosis. 
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FIG. I. Changes in platelet counts after orthotopic liver transplantation 
for hypersplenism. Platelet counts on postoperative days 7, 14,21,30, 
and the recent counts are statistically higher than preoperative values (p 
< 0.05, 0.001, 0.001, 0.001, and 0.001, respectively). POD = postop-
erative day. 
Discussion 
The effect of portasystemic or selective shunt proce-
dures on hypersplenism remains controversial. For por-
tacaval shunts, Sullivan et al. 2 in 1961 and Mitchnick et 
al. 1 in 1980 showed no consistent effect on hypersplenism, 
whereas Morris et al. s in 1962 and Felix et a1. 7 in 1974 
showed persistent correction of hypersplenism, as judged 
by the reduction in the spleen size and the correction of 
the hematologic disorders, in 4 of 8 and 5 of 13 patients, 
respectively. For distal splenorenal shunts, Yang et a1.8 in 
1976 reported no significant change in the platelet counts, 
whereas Hutson et a1.6 in 1977 and Ferrara et al.9 in 1979 
reported a relief of hypersplenism in the majority of pa-
tients, as judged by the improvement of the leukocyte and 
the platelet counts. Also, reports by Puttini et al. 3 in 1979 
and by Soper et al. 4 in 1982, which consisted mainly of 
portasystemic shunts and distal splenorenal shunts, re-
spectively, showed the improvement of the hematolOgic 
disorders and, in the latter, decreased spleen size after the 
shunt procedures. 
Our study demonstrates a dramatic effect of OL Tx on 
hypersplenism, as judged by the changes in the platelet 
counts and the spleen size after OL Tx. Thrombocytopenia 
immediately after OLTx is a common phenomenon due 
to the platelet sequestration and the destruction in the 
liver allograft, 12 but our data show that the platelet counts 
reach a plateau 2 weeks after OLTx and then remain stable 
thereafter. 
The increase in the postoperative platelet counts fol-
lowing OLTx in this series were statistically more signif-
icant in patients with postnecrotic cirrhosis, which may 
be due to the limited number of the patients with other 
diseases. However, the incidence of hypersplenism was 
undoubtedly higher among the patients with postnecrotic 
cirrhosis, either alcoholic or nonalcoholic, as compared 
to other diseases. 
The development of hypersplenism in liver cirrhosis 
has been attributed to splenic congestion.5.6 However, 
other factors such as splenic stimulation from gut-derived 
antigens due to spontaneous portasystemic shuntingl3,14 
have been implicated as a cause, which may explain the 
inconsistent effect of shunt procedures on hypersplenism. 
In general, more collaterals are encountered during OLTx 
for postnecrotic cirrhosis, as compared to other diseases, 
such as primary biliary cirrhosis or sclerosing cholangitis. 
By replacing a cirrhotic liver in the end stage with a non-
cirrhotic allograft, OL Tx not only reduces the portal pres-
sure but also obliterates the collateral circulation, either 
surgically during OLTx or spontaneously after the reduc-
TABLE 3. Comparison of Spleen Size Before and After Orthotopic Liver Transplantation in Patients with Hypersplenism 
Spleen Volume (cc3) 
Case Liver Disease Preoperative* Postoperative* % Changes 
1 PNC-A 753 685 (SO)t -9 
2 PNC-NA 1670 1029 (22)t -38 
3 PNC-NA 699 596 (23lt -15 
4 PNC-NA 595 515 (48)t -13 
5 PNC-NA 951 470 (34)t -50 
6 PNC-NA 1863 1166 (31)t -37 
7 PNC-NA 888 831 (32)t 7 
8 PBC 1912 1605 (60lt -16 
mean ± S.D. 1166 ± 552 861 ± 3!\7 -23.1 ± 16.1 
* p < 0.02 (paired Student's t-test); ( It, number of postoperative 
days; PNC-A, postnecrotic cirrhosis. alcoholic; PNC-NA, postnecrotlc 
cirrhosis, nonalcoholic; PBC, primary biliary cirrhosis. 
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tion of the portal pressure. The degree of collateral for-
mation due to portal hypertension may playa role in the 
development of hypersplenism. 
Although the exact pathogenesis of hypersplenism re-
mains to be elucidated, this series demonstrated that 
OLTx seems to reverse hypersplenism. 
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